Palbociclib/Letrozole Significantly Delayed Progression in Advanced Breast Cancer

Patients with ER-positive, HER2-negative advanced breast cancer had significant delays in progression when palbociclib was added to letrozole treatment, according to the double-blind PALOMA-2 study.

Source: CancerNetwork - November 17, 2016 Category: Cancer & Oncology Authors: Leah Lawrence Tags: Breast Cancer News Source Type: news